Disease modifying antirheumatic drug (DMARD) with immunomodulating activity. Prepn: M. Tanemura et al., DE 2526092; eidem, US 4092426 (1976, 1978 both to Chugai). HPLC determn in plasma: F. J. Schwende, S. W. Turner, Pharm. Res. 8, 523 (1991). Immunosuppression of B cell activity: S. Hirohata et al., Arthritis Rheum. 35, 168 (1992). Clinical trial in rheumatoid arthritis: Y. Shiokawa et al., J. Rheumatol. 11, 615 (1984); in systemic lupus erythematosus: S. Hirohata et al., Clin. Exp. Rheumatol. 12, 261 (1994). Review of pharmacology: R. González, D. Remirez, Invest. Allergol. Clin. Immunol. 7, 77-82 (1997).
Antirheumatic.
Antiarthritic/Antirheumatic